Plasma rico en plaquetas: ¿mito o realidad?

Martínez, A; Ruiz-Santiago, F.; García-Espinosa, J.

doi:10.1016/j.rx.2018.08.006

Cited by 29 publications

(10 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mechanisms of action are attributed to the high concentration of growth factors inducing tissue regeneration and healing. The fibrin frameworks present over platelets support the regenerative matrix leading to the rapid establishment of the proper morphological and molecular configuration for wound healing [1]. Platelet activation by thrombin, calcium chloride, or collagen is required to trigger the release of these growth factors.…”

Section: Introductionmentioning

confidence: 99%

Intraovarian platelet-rich plasma: current status

Elnashar

2021

Middle East Fertil Soc J

View full text Add to dashboard Cite

Background The successful use of PRP in regenerative medicine has led investigators to study its effect in the treatment of conditions like decreased ovarian reserve, poor responders, and premature ovarian insufficiency. Objective To review the uses of intraovarian PRP in reproductive medicine. Methods A literature search for English articles related to the uses of intraovarian PRP in reproductive medicine, including articles published in PubMed, from 2000 to April 2021. Results Seventeen studies: No RCT. Studies were classified according to indication. (1) For diminished ovarian reserve: 6 studies including 369 patients. (2). For poor responders: 3 case series studies including 41 patients with an improvement in ovarian response. (3) For premature ovarian insufficiency: 8 studies including 373 patients. Ovarian reserve markers were the outcome of all studies with conflicting results. LBR was not determined in the majority of studies. Conclusion Intraovarian PRP for diminished ovarian reserve, poor ovarian response, or POI is still experimental. Well-designed, large RCTS to confirm its efficacy and safety are required.

show abstract

Section: Introductionmentioning

confidence: 99%

Intraovarian platelet-rich plasma: current status

Elnashar

2021

Middle East Fertil Soc J

View full text Add to dashboard Cite

show abstract

“…In these cases, previous reports showed success in relieving clinical signs in about 50% of dogs [3,23]. The main advantage of this treatment is that autologous PRP therapy is considered practically harmless [24].…”

Section: Discussionmentioning

confidence: 89%

Platelet-Rich Plasma for the Treatment of Degenerative Lumbosacral Stenosis: A Study with Retired Working Dogs

Hernández-Guerra

Carrillo

Sopena

et al. 2021

Animals

View full text Add to dashboard Cite

Traditionally, canine degenerative lumbosacral stenosis (DLS) has been defined as a multifactorial syndrome characterized by lumbosacral pain triggered by the compression of the nerve rootlets of the cauda equina. There is still no consensus on the treatment of this condition, probably because there are a plethora of possible causes. In addition to compression, inflammation is a very important factor in the physiopathology of the disorder. Platelet-rich plasma (PRP) consists of an increased concentration of autologous platelets suspended in a small amount of plasma. Platelets are a source of several growth factors. Growth factors were shown to help in wound healing and biological processes, such as chemotaxis, neovascularization and synthesis of extracellular matrix, and growth factors were used to improve soft tissue healing and bone regeneration. PRP also facilitates the restoration of the structural integrity of the affected anatomy. Fourteen dogs diagnosed with DLS were treated with three epidural injections of PRP on days 0, 15 and 45. All dogs showed clinical improvement 3 months after the initial treatment. Gait was also objectively assessed by means of the use of force platform analysis before and after treatment, showing significant improvement. The results show that PRP may provide a good alternative to other nonsurgical treatments, such as prednisolone epidural injection.

show abstract

“…17,20 Por otra parte, en las tendinopatías patelares, no se han desarrollado estudios controlados aleatorizados que concluyan sobre el uso de PRP vs terapias conservadoras, por lo que este podría ser utilizado en casos resistentes a la terapia conservadora. 17 Otros autores 19 mencionan que el uso del PRP mejora la regeneración, disminuye el dolor y ayuda en la capacidad funcional del hombro en personas con desgarros del manguito rotador. Además, se menciona que el PRP pobre en leucocitos mejora la curación del tendón con mejores resultados histológicos, por lo que se considera como una mejor medida para el tratamiento clínico de la tendinopatía en comparación con el PRP rico en leucocitos.…”

Section: )unclassified

Tendinopatías: etiología, histopatología y avances terap

Alvarado¹

2019

View full text Add to dashboard Cite

Objetivos: Describir los principales cambios histopatológicos presentes en las tendinopatías, su patogénesis y los avances terapéuticos encontrados en la literatura. Palabras Claves: Tendinopatías, histología, patogénesis, inflamación, tendinosis, regeneración. Materiales y métodos: Se realizó una búsqueda de literatura relacionada con las tendinopatías su patogénesis, cambios histológicos, avances terapéuticos en el uso de células madres, factores de crecimiento (plasma rico en plaquetas) y terapia farmacológica. Se utilizaron las bases de datos de pubmed, clinical key, science direct. Se incluyeron artículos de revisiones bibliográficas entre 2005 al 2018, escritos en inglés. Conclusiones: Las tendinopatías tienen un complejo origen multifactorial, donde los factores extrínsecos e intrínsecos juegan un papel importante para el desarrollo de dicha afectación. La inflamación tiene un rol determinante en el desarrollo de la patogenia de las tendinopatías. La terapia farmacológica antiinflamatoria tiene efectos a corto plazo en la disminución del dolor, sin embargo, resulta contraproducente a largo plazo. Existe controversia sobre el uso del Plasma rico en plaquetas (PRP) y de terapia celular (stem cells), se requiere de mayor investigación que pueda evidenciar la eficacia de dichos tratamientos.

show abstract

Plasma rico en plaquetas: ¿mito o realidad?

Cited by 29 publications

References 67 publications

Intraovarian platelet-rich plasma: current status

Intraovarian platelet-rich plasma: current status

Platelet-Rich Plasma for the Treatment of Degenerative Lumbosacral Stenosis: A Study with Retired Working Dogs

Tendinopatías: etiología, histopatología y avances terap

Contact Info

Product

Resources

About